BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Breast cancer AND ER, estrogen receptor
33591 results:

  • 1. Elucidating the Role of MicroRNA-18a in Propelling a Hybrid Epithelial-Mesenchymal Phenotype and Driving Malignant Progression in ER-Negative breast cancer.
    Nair MG; Mavatkar AD; Naidu CM; V P S; C E A; Rajarajan S; Sahoo S; Mohan G; Jaikumar VS; Ramesh RS; B S S; Jolly MK; Maliekal TT; Prabhu JS
    Cells; 2024 May; 13(10):. PubMed ID: 38786043
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Prognosis and influencing factors of ER-positive, HER2-low breast cancer patients with residual disease after neoadjuvant chemotherapy: a retrospective study.
    Tang L; Jiang L; Shu X; Jin Y; Yu H; Liu S
    Sci Rep; 2024 May; 14(1):11761. PubMed ID: 38783028
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. The Tumor Immune Microenvironment in breast cancer Progression.
    Otterlei Fjørtoft M; Huse K; Rye IH
    Acta Oncol; 2024 May; 63():359-367. PubMed ID: 38779867
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Local intralesional talimogene laherparepvec therapy with complete local response in oral palatine mucosal melanoma: a case report.
    Chitnis SD; Seim NB; Kendra K
    J Med Case Rep; 2024 May; 18(1):257. PubMed ID: 38778387
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Use of Natural Language Understanding to Facilitate Surgical De-Escalation of Axillary Staging in Patients With breast cancer.
    Carleton N; Saadawi G; McAuliffe PF; Soran A; Oesterreich S; Lee AV; Diego EJ
    JCO Clin Cancer Inform; 2024 May; 8():e2300177. PubMed ID: 38776506
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. All-trans-retinoic acid modulates glycolysis via H19 and telomerase: the role of mir-let-7a in estrogen receptor-positive breast cancer cells.
    El Habre R; Aoun R; Tahtouh R; Hilal G
    BMC Cancer; 2024 May; 24(1):615. PubMed ID: 38773429
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Abemaciclib plus endocrine therapy versus chemotherapy after progression on prior palbociclib in HR+/HER2- metastatic breast cancer: A single center real-world study in China.
    Jiang H; Zhong J; Wang J; Song G; Di L; Shao B; Zhang R; Liu Y; Zhu A; Wang N; Li H
    Cancer Med; 2024 May; 13(10):e7249. PubMed ID: 38770648
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. KDM5 family as therapeutic targets in breast cancer: Pathogenesis and therapeutic opportunities and challenges.
    Li CY; Wang W; Leung CH; Yang GJ; Chen J
    Mol Cancer; 2024 May; 23(1):109. PubMed ID: 38769556
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Retrospective analysis of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor-2 (HER2), Ki67 changes and their clinical significance between primary breast cancer and metastatic tumors.
    Qi G; Zhang X; Gai X; Yan X
    PeerJ; 2024; 12():e17377. PubMed ID: 38766488
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Adverse event signal mining and serious adverse event influencing factor analysis of fulvestrant based on FAERS database.
    Yin G; Song G; Xue S; Liu F
    Sci Rep; 2024 May; 14(1):11367. PubMed ID: 38762547
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. The impact of loco-regional treatment modality on the outcomes in breast cancer patients younger than forty years of age.
    Boutrus RR; Abdelazim YA; Mohammed T; Bayomy M; Ibraheem MH; Hussein A; Sebaie ME
    BMC Cancer; 2024 May; 24(1):599. PubMed ID: 38760780
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Isolation and Characterization of a Novel Mammary Adenocarcinoma, MCa-P1362, with Hormone receptor Expression, Human Epidermal Growth Factor receptor 2 Positivity, and Enrichment in cancer and Mesenchymal Stem Cells.
    Jana S; Li W; Lei PJ; Wang Z; Kibara S; Huang P; Jones D
    Am J Pathol; 2024 Jun; 194(6):1137-1153. PubMed ID: 38749609
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Tumor-associated NK cells drive MDSC-mediated tumor immune tolerance through the IL-6/STAT3 axis.
    Neo SY; Tong L; Chong J; Liu Y; Jing X; Oliveira MMS; Chen Y; Chen Z; Lee K; Burduli N; Chen X; Gao J; Ma R; Lim JP; Huo J; Xu S; Alici E; Wickström SL; Haglund F; Hartman J; Wagner AK; Cao Y; Kiessling R; Lam KP; Westerberg LS; Lundqvist A
    Sci Transl Med; 2024 May; 16(747):eadi2952. PubMed ID: 38748775
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. RPGRIP1L as a new biomarker for prognosis and tumor immune of breast cancer.
    Yi J; Liu L; Chen Y; Ding T; Fan P; Yu J; Zeng J
    FASEB J; 2024 May; 38(9):e23624. PubMed ID: 38747001
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. FGFR2-triggered autophagy and activation of Nrf-2 reduce breast cancer cell response to anti-ER drugs.
    Gorska-Arcisz M; Popeda M; Braun M; Piasecka D; Nowak JI; Kitowska K; Stasilojc G; Okroj M; Romanska HM; Sadej R
    Cell Mol Biol Lett; 2024 May; 29(1):71. PubMed ID: 38745155
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Axillary lymph node metastasis in pure mucinous carcinoma of breast: clinicopathologic and ultrasonographic features.
    Li N; Li JW; Qian Y; Liu YJ; Qi XZ; Chen YL; Gao Y; Chang C
    BMC Med Imaging; 2024 May; 24(1):108. PubMed ID: 38745134
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Clinical and economic outcomes of adding [18F]FES PET/CT in estrogen receptor status identification in metastatic and recurrent breast cancer in the US.
    Munter-Young R; Fuentes-Alburo A; DiGregorio N; Neeser K; Gultyaev D
    PLoS One; 2024; 19(5):e0302486. PubMed ID: 38743917
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Neoadjuvant radiotherapy in ER
    Bruss C; Albert V; Seitz S; Blaimer S; Kellner K; Pohl F; Ortmann O; Brockhoff G; Wege AK
    Front Immunol; 2024; 15():1355130. PubMed ID: 38742103
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Estetrol/GPER/SERPINB2 transduction signaling inhibits the motility of triple-negative breast cancer cells.
    Cirillo F; Spinelli A; Talia M; Scordamaglia D; Santolla MF; Grande F; Rizzuti B; Maggiolini M; Gérard C; Lappano R
    J Transl Med; 2024 May; 22(1):450. PubMed ID: 38741146
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Metabolism-driven in vitro/in vivo disconnect of an oral ERɑ VHL-PROTAC.
    Hayhow TG; Williamson B; Lawson M; Cureton N; Braybrooke EL; Campbell A; Carbajo RJ; Cheraghchi-Bashi A; Chiarparin E; Diène CR; Fallan C; Fisher DI; Goldberg FW; Hopcroft L; Hopcroft P; Jackson A; Kettle JG; Klinowska T; Künzel U; Lamont G; Lewis HJ; Maglennon G; Martin S; Gutierrez PM; Morrow CJ; Nikolaou M; Nissink JWM; O'Shea P; Polanski R; Schade M; Scott JS; Smith A; Weber J; Wilson J; Yang B; Crafter C
    Commun Biol; 2024 May; 7(1):563. PubMed ID: 38740899
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 1680.